Based on ex vivo drug screening, MM with TP53mut may be targetable by approved inhibitors of mitosis, topoisomerase, HDAC, HSP90, IGF1R and PI3K/AKT/mTOR pathways (Tsallos et al. 2024). This evidence concerns the gene MTOR and Miyoshi myopathy.